FDA Approves ORLADEYO® 150 mg Oral Pellets for Hereditary Angioedema (HAE)

BioCryst Pharmaceuticals has announced that the U.S. FDA has approved a supplemental New Drug Application (sNDA) for ORLADEYO® (berotralstat) 150 mg oral pellets. This new formulation provides an alternative administration option for adults and adolescents aged 12 years and older with hereditary angioedema (HAE) who may have difficulty swallowing capsules. ORLADEYO is a once-daily oral prophylactic therapy designed to prevent HAE attacks.